Related Experiment Video
Updated: Aug 8, 2026

Myelin Oligodendrocyte Glycoprotein (MOG35-55) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice
Published on: April 16, 2014
Cell-based gene therapy experiments in murine experimental autoimmune encephalomyelitis
1Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Gene therapy using modified fibroblasts effectively treats experimental autoimmune encephalomyelitis (EAE), a multiple sclerosis (MS) model. This approach shows promise for developing novel MS treatments by reducing disease severity.
Area of Science:
- Immunology
- Neuroscience
- Gene Therapy
Background:
- Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Experimental autoimmune encephalomyelitis (EAE) serves as a key animal model for studying MS pathogenesis and testing potential therapies.
Purpose of the Study:
- To develop and evaluate a cell-based gene therapy protocol for treating EAE.
- To investigate the efficacy of transduced fibroblasts secreting specific antigens in ameliorating EAE.
- To optimize the gene delivery system for potential clinical translation in MS treatment.
Main Methods:
- Development of fibroblast cell lines engineered to secrete encephalitogenic epitopes (from myelin basic protein and proteolipid protein).
- Administration of these transduced fibroblasts to mice with established EAE.
- Evaluation of disease severity and therapeutic effects.
- Testing of sequestered cells within implantable chambers and modified mini-gene constructs.
Main Results:
- Injected transduced fibroblasts significantly abrogated EAE disease progression.
- Both myelin basic protein and proteolipid protein mini-gene constructs were effective in ameliorating EAE.
- Therapeutic efficacy was observed with both syngeneic and allogeneic cells, particularly when sequestered in implantable chambers.
- Modification of signal sequences reduced the required cell dose for effective treatment.
Conclusions:
- Cell-based gene therapy using engineered fibroblasts is a viable strategy for treating EAE.
- The approach demonstrates potential for novel therapeutic interventions in multiple sclerosis.
- Optimizations in cell delivery and antigen expression enhance the feasibility of clinical application.
More Related Videos
08:47Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues
Published on: May 8, 2016
05:55Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
Published on: December 1, 2023